Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1259

1.

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr.

J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5.

PMID:
28886926
2.

Statins for children with familial hypercholesterolemia.

Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, Ramaswami U.

Cochrane Database Syst Rev. 2017 Jul 7;7:CD006401. doi: 10.1002/14651858.CD006401.pub4. Review.

PMID:
28685504
3.

ScreenPro FH: from the Czech MedPed to international collaboration. ScreenPro FH is a participating project of the EAS-FHCS.

Ceska R, Freiberger T, Vaclova M, Aleksicova T, Votavova L, Vrablik M.

Physiol Res. 2017 Apr 5;66(Supplementum 1):S85-S90. Review.

4.

Molecular genetic background of an autosomal dominant hypercholesterolemia in the Czech Republic.

Tichý L, Fajkusová L, Zapletalová P, Schwarzová L, Vrablík M, Freiberger T.

Physiol Res. 2017 Apr 5;66(Supplementum 1):S47-S54. Review.

5.

Familial hypercholesterolemia in the Czech Republic: more than 17 years of systematic screening within the MedPed project.

Vrablík M, Vaclová M, Tichý L, Soška V, Bláha V, Fajkusová L, Češka R, Šatný M, Freiberger T.

Physiol Res. 2017 Apr 5;66(Supplementum 1):S1-S9. Review.

6.

PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payers.

Baum SJ, Toth PP, Underberg JA, Jellinger P, Ross J, Wilemon K.

Clin Cardiol. 2017 Apr;40(4):243-254. doi: 10.1002/clc.22713. Epub 2017 Mar 22. Review.

7.

Alirocumab for the treatment of hypercholesterolemia.

Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM.

Expert Opin Biol Ther. 2017 May;17(5):633-643. doi: 10.1080/14712598.2017.1305354. Epub 2017 Mar 20. Review.

PMID:
28277798
8.

Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors to Reduce Cardiovascular Inflammation and Outcomes.

Liberale L, Montecucco F, Camici GG, Dallegri F, Vecchie A, Carbone F, Bonaventura A.

Curr Med Chem. 2017;24(14):1403-1416. doi: 10.2174/0929867324666170303123734. Review.

PMID:
28260498
9.

Cellular uptake and trafficking of antisense oligonucleotides.

Crooke ST, Wang S, Vickers TA, Shen W, Liang XH.

Nat Biotechnol. 2017 Mar;35(3):230-237. doi: 10.1038/nbt.3779. Epub 2017 Feb 27. Review.

PMID:
28244996
10.

2017 Taiwan lipid guidelines for high risk patients.

Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI; Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients.

J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24. Review.

11.

Barriers to the Implementation of Lipoprotein Apheresis in Canada.

Filler G, Lee M, Hegele RA.

Can J Cardiol. 2017 Mar;33(3):409-411. doi: 10.1016/j.cjca.2017.01.008. Epub 2017 Jan 21. Review.

PMID:
28232020
12.

[Treatment with statins in children with familial hypercholesterolemia].

Kamińska E, Hennig M, Brandt A, Bautembach Minkowska J, Myśliwiec M.

Dev Period Med. 2016;20(4):328-334. Review. Polish.

13.

Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan.

Mabuchi H.

J Atheroscler Thromb. 2017 Mar 1;24(3):189-207. doi: 10.5551/jat.RV16008. Epub 2017 Feb 8. Review.

14.

[Molecular genetics of hypercholesterolemia].

Schwarzová L.

Vnitr Lek. Fall 2016;62(11):877-881. Review. Czech.

PMID:
28128573
15.

[PCSK9 inhibitors : Current clinical relevance].

Vogt A.

Internist (Berl). 2017 Feb;58(2):196-201. doi: 10.1007/s00108-016-0179-7. Review. German.

PMID:
28083599
16.

Bococizumab for the treatment of hypercholesterolaemia.

Ferri N, Corsini A, Sirtori CR, Ruscica M.

Expert Opin Biol Ther. 2017 Feb;17(2):237-243. doi: 10.1080/14712598.2017.1279602. Review.

17.

An Evidence-Based Guide to Cholesterol-Lowering Guidelines.

Waters DD, Boekholdt SM.

Can J Cardiol. 2017 Mar;33(3):343-349. doi: 10.1016/j.cjca.2016.10.019. Epub 2016 Oct 24. Review.

PMID:
28034582
18.

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?

Preiss D, Mafham M.

Diabetologia. 2017 Mar;60(3):381-389. doi: 10.1007/s00125-016-4178-y. Epub 2016 Dec 26. Review.

PMID:
28025677
19.

microRNAs in lipoprotein and lipid metabolism: from biological function to clinical application.

Desgagné V, Bouchard L, Guérin R.

Clin Chem Lab Med. 2017 May 1;55(5):667-686. doi: 10.1515/cclm-2016-0575. Review.

20.

Homozygous familial hypercholesterolaemia: update on management.

France M.

Paediatr Int Child Health. 2016 Nov;36(4):243-247. Review.

PMID:
27967828

Supplemental Content

Loading ...
Support Center